文献速递头颈外科小儿耳鼻咽喉

老年头颈癌患者术后持续性阿片类药物使用研究

Persistent Postoperative Opioid Use in Older Head and Neck Cancer Patients.
PubMed 文献 · Otolaryngol Head Neck Surg · 2018-05-29

该回顾性队列研究基于SEER-Medicare数据库,纳入2008至2013年确诊并接受原发手术切除的66岁以上头颈癌患者1190例。术后90至180天新开阿片类处方定义为持续性术后阿片使用(PPO),866例术后获阿片处方的患者中PPO总体发生率为33.3%,术前阿片使用者为48.3%,未使用者为18.5%,术后放疗与合并症指数亦与PPO相关。

要点

  • 老年头颈癌术后患者PPO总体发生率为33.3%,问题不容忽视
  • 术前阿片使用者的PPO风险显著高于未使用者(48.3%对18.5%)
  • 术后放疗与Charlson合并症指数升高亦与PPO使用相关

核心结论

  • 持续性术后阿片使用在老年头颈癌手术患者中较为普遍,需考虑替代治疗策略并持续审视处方指南。

研究设计与样本

  • 回顾性队列研究,数据来自SEER-Medicare癌症登记与理赔链接数据库。
  • 纳入2008至2013年确诊头颈癌、年龄66岁及以上、接受原发手术切除并符合保险与出院标准的患者,共1190例。
  • 主要结局为术后90至180天新开阿片类处方所定义的持续性术后阿片使用(PPO)。
  • 采用多因素logistic回归评估PPO与人口学及术后治疗等因素的关联。

主要发现

  • 1190例合格患者中866例(72.8%)因手术获得阿片类处方。
  • 866例中PPO总体发生率为33.3%。
  • 术前阿片使用者428例中PPO为48.3%,未使用者438例中为18.5%(校正OR 3.96;95%CI 2.80-5.59)。
  • 术后放疗与PPO相关(OR 1.99;95%CI 1.33-2.98)。
  • Charlson合并症指数与PPO相关(OR 1.20;95%CI 1.03-1.41);术后化疗无显著关联(OR 1.19;95%CI 0.73-1.95)。

关键数值与推荐

  • PPO定义:术后90至180天新开阿片类处方。
  • 术前阿片使用与PPO的校正OR为3.96(95%CI 2.80-5.59)。
  • 术后放疗与PPO的OR为1.99(95%CI 1.33-2.98)。
  • Charlson合并症指数与PPO的OR为1.20(95%CI 1.03-1.41)。
  • 术后化疗与PPO的OR为1.19(95%CI 0.73-1.95),无统计学显著性。

临床怎么用

  • 对老年头颈癌手术患者应评估术前阿片使用史,识别PPO高危人群。
  • 对接受术后放疗或合并症较多的患者,围手术期应加强阿片处方管理与随访。
  • 可考虑替代镇痛策略并参照处方指南,减少术后长期阿片使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite the epidemic of opioid overuse among American patients, there are limited data regarding the prevalence of such use among patients with head and neck cancer (HNC). Here, we report on the prevalence of persistent postoperative opioid (PPO) use and its risk factors among older patients with HNC undergoing surgery. STUDY DESIGN: Retrospective cohort study. SETTING: Surveillance, Epidemiology, and End Results (SEER)-Medicare linked cancer registry-claims database. SUBJECTS AND METHODS: We identified patients aged 66 years or older who were diagnosed with HNC from 2008 to 2013, underwent primary surgical resection for their cancers, and met certain insurance and discharge criteria. The primary outcome was PPO use, defined as new opioid prescriptions 90 to 180 days postoperatively. We used multivariable logistic regression to evaluate associations between PPO use and factors such as demographics and postoperative treatment. RESULTS: Of the 1190 eligible patients with HNC, 866 (72.8%) received opioid prescriptions attributable to their surgery. Among these 866 patients, the prevalence of PPO use was 33.3% overall; it was 48.3% among the 428 patients with preoperative opioid use compared to 18.5% among the 438 opioid-naive patients (adjusted odds ratio [OR], 3.96; 95% confidence interval [CI], 2.80-5.59). Other factors associated with PPO use include postoperative radiotherapy (OR, 1.99; 95%, CI 1.33-2.98) and Charlson comorbidity index (OR, 1.20; 95% CI, 1.03-1.41). Postoperative chemotherapy (OR, 1.19; 95% CI, 0.73-1.95) was not significantly associated with PPO use. CONCLUSIONS: PPO use is a substantial problem in older surgical patients with HNC, one that warrants consideration of alternative treatment strategies and continued examination of prescription guidelines for patients with HNC.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Saraswathula A, Chen MM, Mudumbai SC, et al. Persistent Postoperative Opioid Use in Older Head and Neck Cancer Patients. Otolaryngol Head Neck Surg. 2018. PMID: 29807503. doi:10.1177/0194599818778276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。